Evidence map›Paper›PMID 39456904›Full record

ArticleInternational journal of molecular sciences2024

High-Throughput Luminescence-Based Serum Bactericidal Assay Optimization and Characterization to Assess Human Sera Functionality Against Multiple

Valentina Caradonna, Marika Pinto, Renzo Alfini, Carlo Giannelli, Miren Iturriza, Francesca Micoli, Omar Rossi, Francesca Mancini

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valentina CaradonnaLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.ORCID 0000-0003-3092-125X
Marika PintoGSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.
Renzo AlfiniGSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.ORCID 0000-0001-7103-0723
Carlo GiannelliGSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.ORCID 0000-0002-6112-6841
Miren IturrizaGSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.
Francesca MicoliGSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.
Omar RossiGSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.ORCID 0000-0002-0170-1285
Francesca ManciniGSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.ORCID 0000-0003-2122-9480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shigellosis represents a significant global health concern particularly affecting children under 5 years in low- and middle-income countries (LMICs) and is associated with stunting and antimicrobial resistance. There is a critical need for an effective vaccine offering broad protection against the different

Indexed as

SerogroupShigella flexneriAnimalsAntibodies, BacterialBlood Bactericidal ActivityDysentery, BacillaryHigh-Throughput Screening AssaysHumansImmunoglobulin GLuminescenceLuminescent MeasurementsO AntigensRabbitsAntibodies, BacterialImmunoglobulin GO Antigensfunctional assayhuman serumSBAShigellavaccine

Identifiers

PMID39456904
PMCPMC11508014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.